We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A large study published in the latest issue of Archives of Neurology found no evidence that statins or other cholesterol-lowering treatments reduced the risk of developing dementia from Alzheimer's disease, vascular dementia
or the two conditions combined.
Advanced Viral Research has added Queens Medical Associates in New York as a
new clinical site for its Phase II, multicenter clinical trial of AVR118 in
the U.S. Other participating sites include North Shore University Hospital of
New York and Jacobi Medical Center, both in New York, and the Medical Center
of Vincennes in Indiana.
Nabi Biopharmaceuticals announced results from the first in a series of immunogenicity
studies of StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine)
in additional patient populations at risk for S. aureus infections.
ID Biomedical announced it has been advised by the FDA's Center for Biologics
Evaluation and Research that the company's influenza virus vaccine (Fluviral)
has been granted a fast-track designation.
NPS Pharmaceuticals has announced that as of July 9, 2005, the FDA has accepted
for review the company's new drug application (NDA) to market Preos (parathyroid
hormone) for the treatment of osteoporosis in postmenopausal women.
Bayer Pharmaceuticals and Onyx Pharmaceuticals announced that the companies
have completed the submission of a New Drug Application (NDA) with the FDA for
sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma, or
kidney cancer.
The FDA has granted Indian drugmaker Aurobindo Pharma tentative approval to
manufacture fixed-dose combination lamivudine and zidovudine tablets for use
outside the U.S.